Fagron NV (EBR:FAGR)

Market Cap	1.40B
Revenue (ttm)	871.96M
Net Income (ttm)	80.55M
Shares Out	72.84M
EPS (ttm)	1.10
PE Ratio	17.47
Forward PE	14.24
Dividend	0.35 (1.82%)
Ex-Dividend Date	May 21, 2024

Volume	40,688
Average Volume	49,257
Open	19.38
Previous Close	19.24
Day's Range	19.10 - 19.38
52-Week Range	15.14 - 20.15
Beta	0.27
RSI	58.06
Earnings Date	Jul 31, 2025

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan use...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 3,828
• Stock Exchange: Euronext Brussels
• Ticker Symbol: FAGR

Financial Performance

In 2024, Fagron NV's revenue was 871.96 million, an increase of 14.28% compared to the previous year's 762.99 million. Earnings were 80.55 million, an increase of 14.18%.